The Principles of Clinical Cytogenetics - Extra Materials - Springer

448 Jonathan Fletcher
91. Knezevich, S.R., McFadden, D.E., Tao, W., Lim, J.F. and Sorensen, P.H. (1998) A novel ETV6–NTRK3 gene fusion in
congenital fibrosarcoma. Nature Genet. 18, 184–187.
92. Rubin, B.P., Chen, C.J., Morgan, T.W., et al. (1998) Congenital mesoblastic nephroma t(12;15) is associated with
ETV6–NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am. J.
Pathol. 153, 1451–1458.
93. Knezevich, S.R., Garnett, M.J., Pysher, T.J., Beckwith, J.B., Grundy, P.E., and Sorensen, P.H. (1998) ETV6–NTRK3
gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma.
Cancer Res. 58, 5046–5048.
94. Treissman, S.P., Gillis, D.A., Lee, C.L., Giacomantonio, M., and Resch, L. (1994) Omental-mesenteric inflammatory
pseudotumor. Cytogenetic demonstration of genetic changes and monoclonality in one tumor. Cancer 73, 1433–1437.
95. Snyder, C.S., Dell’Aquila, M., Haghighi, P., Baergen, R.N., Suh, Y.K., and Yi, E.S. (1995) Clonal changes in inflammatory
pseudotumor of the lung: a case report. Cancer 76, 1545–1549.
96. Su, L.D., Atayde-Perez, A., Sheldon, S., Fletcher, J.A., and Weiss, S.W. (1998) Inflammatory myofibroblastic tumor:
cytogenetic evidence supporting clonal origin. Mod. Pathol. 11, 364–368.
97. Lawrence, B., Perez-Atayde, A., Hibbard, M.K., et al. (2000) TPM3-ALK and TPM4-ALK oncogenes in inflammatory
myofibroblastic tumors. Am. J. Pathol. 157, 377–384.
98. Hirota, S., Isozaki, K., Moriyama, Y., et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal
tumors. Science 279, 577–580.
99. Rubin, B.P., Singer, S., Tsao, C., et al. (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Cancer Res. 61, 8118–8121.
100. Heinrich, M.C., Corless, C.L., Duensing, A., et al. (2003) PDGFRA activating mutations in gastrointestinal stromal
tumors. Science 299, 708–710.
101. Demetri, G.D., von Mehren, M., Blanke, C.D., et al. (2002) Efficacy and safety of imatinib mesylate in advanced
gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472–480.
102. van Oosterom, A.T., Judson, I., Verweij, J., et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal
stromal tumours: a phase I study. Lancet 358, 1421–1423.
103. Nishida, T., Hirota, S., Taniguchi, M., et al. (1998) Familial gastrointestinal stromal tumours with germline mutation of
the KIT gene. Nature Genet. 19, 323–324.
104. Sarlomo-Rikala, M., el-Rifai, W., Lahtinen, T., Andersson, L.C., Miettinen, M., and Knuutila, S. (1998) Different
patterns of DNA copy number changes in gastrointestinal stromal tumors, leiomyomas, and schwannomas. Hum. Pathol.
29, 476–481.
105. el Rifai, W., Sarlomo-Rikala, M., Andersson, L.C., Knuutila, S., and Miettinen, M. (2000) DNA sequence copy number
changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res. 60, 3899–3903.
106. Schneider-Stock, R., Boltze, C., Lasota, J., et al. (2003) High prognostic value of p16INK4 alterations in gastrointestinal
stromal tumors. J. Clin. Oncol. 21, 1688–1697.
107. Legius, E., Marchuk, D.A., Collins, F.S., and Glover, T.W. (1993) Somatic deletion of the neurofibromatosis type 1
gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nature Genet. 3, 122–126.
108. Basu, T.N., Gutmann, D.H., Fletcher, J.A., Glover, T.W., Collins, F.S., and Downward, J. (1992) Aberrant regulation
of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356, 713–715.
109. DeClue, J.E., Papageorge, A.G., Fletcher, J.A., et al. (1992) Abnormal regulation of mammalian p21ras contributes to
malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69, 265–273.
110. Rouleau, G.A., Merel, P., Lutchman, M., et al. (1993) Alteration in a new gene encoding a putative membrane-organizing
protein causes neuro-fibromatosis type 2. Nature 363, 515–521.
111. Twist, E.C., Ruttledge, M.H., Rousseau, M., et al. (1994) The neurofibromatosis type 2 gene is inactivated in
schwannomas. Hum. Mol. Genet. 3, 147–151.
112. Lutchman, M. and Rouleau, G.A. (1995) The neurofibromatosis type 2 gene product, schwannomin, suppresses growth
of NIH 3T3 cells. Cancer Res. 55, 2270–2274.
113. Kluwe, L., Friedrich, R., and Mautner, V.-F. (1999) Loss of NF1 allele in Schwann cells but not in fibroblasts dervied
from an NF1-associated neurofibroma. Genes Chromosomes Cancer 24, 283–285.
114. Murthy, S.S. and Testa, J.R. (1999) Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human
malignant mesothelioma. J. Cell Physiol. 180, 150–157.
115. Lechner, J.F., Tokiwa, T., LaVeck, M., et al. (1985) Asbestos-associated chromosomal changes in human mesothelial
cells. Proc. Natl. Acad. Sci. USA 82, 3884–3888.
116. Ault, J.G., Cole, R.W., Jensen, C.G., Jensen, L.C.W., Bachert, L.A., and Rieder, C.L. (1995) Behavior of crocidolite
asbestos during mitosis in living vertebrate lung epithelial cells. Cancer Res. 55, 792–798.
117. Hayashi, Y., Inaba, T., Hanada, R., and Yamamoto, K. (1988) Chromosome findings and prognosis in 15 patients with
neuroblastoma found by VMA mass screening. J. Pediatr. 112, 567–571.
118. Brodeur, G.M., Azar, C., Brother, M., et al. (1992) Neuroblastoma. Effect of genetic factors on prognosis and treatment.
Cancer 70, 1685–1694.